Overview

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

This study is an open-label, dose-finding study to determine the target or maximum-tolerated dose and to characterize the safety and pharmacokinetic profile of AMG 706 administered in combination with erlotinib with or without gemcitabine in subjects with solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Erlotinib Hydrochloride
Gemcitabine
Motesanib diphosphate
Niacinamide